140 related articles for article (PubMed ID: 21593190)
1. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people.
Dekker F; Wiendels NJ; de Valk V; van der Vliet C; Knuistingh Neven A; Assendelft WJ; Ferrari MD
Cephalalgia; 2011 Jun; 31(8):943-52. PubMed ID: 21593190
[TBL] [Abstract][Full Text] [Related]
2. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
3. Triptan use in Italy: Insights from administrative databases.
Da Cas R; Nigro A; Terrazzino S; Sances G; Viana M; Tassorelli C; Nappi G; Cargnin S; Pisterna A; Traversa G; Genazzani AA
Cephalalgia; 2015 Jun; 35(7):619-26. PubMed ID: 25246521
[TBL] [Abstract][Full Text] [Related]
4. Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study.
Ferrari A; Baraldi C; Licata M; Vandelli D; Marchesi F; Palazzoli F; Verri P; Rustichelli C; Giuliani E; Silingardi E
Eur J Clin Pharmacol; 2016 Sep; 72(9):1075-81. PubMed ID: 27245458
[TBL] [Abstract][Full Text] [Related]
5. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
Headache; 2004; 44(7):661-8. PubMed ID: 15209687
[TBL] [Abstract][Full Text] [Related]
6. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2008 Feb; 48(2):236-47. PubMed ID: 18179569
[TBL] [Abstract][Full Text] [Related]
8. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
Zebenholzer K; Gall W; Wöber C
J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoepidemiology of triptans in a headache centre.
Ferrari A; Spaccapelo L; Sternieri E
Cephalalgia; 2010 Jul; 30(7):847-54. PubMed ID: 20647176
[TBL] [Abstract][Full Text] [Related]
10. Risk of ischemic complications related to the intensity of triptan and ergotamine use.
Wammes-van der Heijden EA; Rahimtoola H; Leufkens HG; Tijssen CC; Egberts AC
Neurology; 2006 Oct; 67(7):1128-34. PubMed ID: 17030745
[TBL] [Abstract][Full Text] [Related]
11. Twenty-five years of triptans - a nationwide population study.
Davidsson OB; Olofsson IA; Kogelman LJ; Andersen MA; Rostgaard K; Hjalgrim H; Olesen J; Hansen TF
Cephalalgia; 2021 Jul; 41(8):894-904. PubMed ID: 33583217
[TBL] [Abstract][Full Text] [Related]
12. Rational migraine management: optimising treatment with the triptans.
Millson DS
Funct Neurol; 2000; 15 Suppl 3():182-91. PubMed ID: 11200789
[TBL] [Abstract][Full Text] [Related]
13. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
[TBL] [Abstract][Full Text] [Related]
14. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
15. Triptan use in Australia 1997-2015: A pharmacoepidemiological study.
Eyre BLKD; Eadie MJ; van Driel ML; Ross-Lee L; Hollingworth SA
Acta Neurol Scand; 2017 Aug; 136(2):155-159. PubMed ID: 28093722
[TBL] [Abstract][Full Text] [Related]
16. [Self-medication of regular headache: a community pharmacy-based survey in Belgium].
Mehuys E; Paemeleire K; Van Hees T; Christiaens T; Van Bortel L; Van Tongelen I; Philippe G; Prévôt ML; Evrard B; Piette M; De Bolle L; Remon JP; Boussery K
J Pharm Belg; 2012 Jun; (2):4-10. PubMed ID: 22978009
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of medication overuse headache in the general Swedish population.
Jonsson P; Hedenrud T; Linde M
Cephalalgia; 2011 Jul; 31(9):1015-22. PubMed ID: 21628444
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
19. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
[TBL] [Abstract][Full Text] [Related]
20. Glutamate levels in cerebrospinal fluid and triptans overuse in chronic migraine.
Vieira DS; Naffah-Mazzacoratti Mda G; Zukerman E; Senne Soares CA; Cavalheiro EA; Peres MF
Headache; 2007 Jun; 47(6):842-7. PubMed ID: 17578532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
